Modality
Bispecific Ab
MOA
PARPi
Target
USP1
Pathway
NF-κB
HS
Development Pipeline
Preclinical
~Feb 2015
→ ~May 2016
Phase 1
~Aug 2016
→ ~Nov 2017
Phase 2
~Feb 2018
→ ~May 2019
Phase 3
~Aug 2019
→ ~Nov 2020
NDA/BLA
~Feb 2021
→ ~May 2022
Approved
Aug 2022
→ Dec 2028
ApprovedCurrent
NCT06462524
230 pts·HS
2022-08→2028-12·Not yet recruiting
230 total pts1 indication
CompletedCurrentUpcoming
Catalysts (2)
2026-08-235mo awayOrphan Drug· HS
2028-12-132.7y awayPh3 Readout· HS
Trial Timeline
Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
Approved
Not yet…
Catalysts
Orphan Drug
2026-08-23 · 5mo away
HS
Ph3 Readout
2028-12-13 · 2.7y away
HS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06462524 | Approved | HS | Not yet recr... | 230 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| GSK-6516 | GSK | Phase 1/2 | MALT1 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| BNT-5232 | BioNTech | NDA/BLA | TIGIT | |
| ALN-3958 | Alnylam | Phase 2 | MALT1 | |
| Cevifotisoran | Neurocrine | Approved | CD47 | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| UTH-9370 | United Therapeutics | NDA/BLA | TIGIT |